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Introduction
Pancreatic cancer is one of the most dreaded malignant 
diseases. It ranks the fourth most common cause of cancer- 
related death in many Western countries and has a remark-
ably dismal prognosis with a 5- year survival rate of <5% 
[1]. The manifestation of symptoms occurs relatively late 
in the disease process. Most pancreatic cancer cases are 
therefore diagnosed at an unresectable stage and only 
15–20% of the patients undergo surgical resection, which 
is the only potentially curative treatment.
Histologically, the large majority of pancreatic cancer 
cases are exocrine and classified as pancreatic ductal 
adenocarcinoma (PDAC), in which the characteristic mor-
phological pattern consists of abundant duct- like neoplastic 
structures embedded in a dense desmoplastic stroma [2]. 
Accepted risk factors for PDAC include advanced age, 
cigarette smoking [3], and long- standing chronic 
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Abstract
Both serology- based and genetic studies have reported an association between 
pancreatic cancer risk and ABO blood groups. We have investigated this rela-
tionship in a cohort of pancreatic cancer patients from Western Norway (n = 237) 
and two control materials (healthy blood donors, n = 379; unselected hospital-
ized patients, n = 6149). When comparing patient and blood donor ABO allele 
frequencies, we found only the A1 allele to be associated with significantly higher 
risk for pancreatic ductal adenocarcinoma (PDAC) (23.8% vs. 17.9%; OR = 1.43, 
P = 0.018). Analyzing phenotypes, blood group A was more frequent among 
PDAC cases than blood donors (50.8% vs. 40.6%; OR = 1.51, P = 0.021), an 
enrichment fully explained by the A1 subgroup. Blood group O frequency was 
lower in cases than in blood donors (33.8% vs. 42.7%; OR = 0.69, P = 0.039). 
This lower frequency was confirmed when cases were compared to hospitalized 
patients (33.8% vs. 42.9%; OR = 0.68, P = 0.012). Results for blood group B 
varied according to which control cohort was used for comparison. When pa-
tients were classified according to surgical treatment, the enrichment of blood 
group A was most prominent among unresected cases (54.0%), who also had 
the lowest prevalence of O (28.7%). There was a statistically significant better 
survival (P = 0.04) for blood group O cases than non- O cases among unresected 
but not among resected patients. Secretor status did not show an association 
with PDAC or survival. Our study demonstrates that pancreatic cancer risk is 
influenced by ABO status, in particular blood groups O and A1, and that this 
association may reflect also in tumor resectability and survival.
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pancreatitis [4], whereas some studies also have implicated 
Helicobacter pylori infection [5] and diabetes mellitus [6]. 
In addition, inherited susceptibility plays a role in the 
disease, both as high- risk gene variants in the context of 
familial cancer syndromes [7] and as the presence of vari-
ants with modest effect, usually discovered by genome- wide 
association studies (GWAS) [8].
In a landmark GWAS paper, the Pancreatic Cancer 
Cohort Consortium (PanScan) reported that the statisti-
cally most significant variants associating with pancreatic 
cancer risk belonged to the ABO locus on chromosome 
9q34 [9]. ABO codes for a glycosyltransferase that gives 
rise to the histo- blood group antigens of the ABO system. 
Single- nucleotide polymorphisms (SNPs) of this gene 
determine the specificity of the enzyme [10, 11]. Hence, 
by adding either N- acetyl- d- galactosamine or d- galactose 
to the precursor H antigen, the A and B glycosyltrans-
ferases produce A or B antigens, respectively, on cellular 
surfaces and secretions. A frequent ABO variant is a one- 
base pair deletion that inactivates the encoded enzyme, 
leaving the H antigen unaltered and corresponding to the 
O phenotype [10]. This deletion is in strong linkage dis-
equilibrium with the T allele of SNP rs505922, which 
was identified as being associated with decreased suscep-
tibility for pancreatic cancer [9]. Accordingly, individuals 
with blood group O have a lower risk for this disease 
than those with other blood groups [12].
There are two major subtypes of the ABO allele deter-
mining the blood group A, namely A1 and A2. Data from 
PanScan demonstrated that, among all common ABO 
variants, the greatest risk of pancreatic cancer was con-
ferred by the A1 allele [13] which gives rise to the ABO 
protein with highest enzymatic activity [14]. This finding 
suggests that it is the glycosyltransferase activity itself 
that is linked to cancer risk rather than actions of other 
nearby genes on chromosome 9q34. Somewhat surpris-
ingly though, the association between blood group and 
pancreatic cancer was not influenced by the secretor 
phenotype, that is, a person’s ability to secrete A, B, and 
H antigens into body fluids [13]. This property is deter-
mined by FUT2, the gene encoding the glycosylating 
enzyme fucosyltransferase 2.
The initial reports [9, 12, 13] were followed up by 
genetic studies in various populations that confirmed the 
influence of ABO blood group alleles on pancreatic cancer 
risk [15–17]. The finding that blood group O confers 
protection was also consistent with older papers that had 
reported an association between ABO phenotype and gas-
trointestinal cancers including pancreatic cancer [18–20]. 
A meta- analysis including over 20 studies, both genetic 
and serology- based, concluded that all non- O blood groups 
have elevated risks for pancreatic cancer as compared with 
the O phenotype [16].
In this study, we aimed at evaluating the link between 
pancreatic cancer and ABO histo- blood groups in patients 
from Norway, a population in which this association has 
not yet been investigated. Our patients were carefully 
characterized to exclude non- PDAC cases and also clas-
sified according to tumor resectability and survival. Two 




The study was performed according to the Helsinki 
Declaration and all patients gave their written informed 
consent. The project was approved by the Regional Ethical 
Committee of Western Norway. The patient cohort con-
sisted of 237 cases of pancreatic adenocarcinoma seen at 
Haukeland University Hospital, Bergen, Norway between 
the years 1998 and 2012 (Table 1). Medical records, 
pathology reports, and/or tissue sections were examined 
by two pathologists (HI and SA) for diagnosis confirma-
tion. Final classification resulted in 195 PDAC cases and 









All pancreatic adenocarcinoma cases 237 119 50.2 69 118 49.8 69
Pancreatic ductal adenocarcinoma (PDAC) 195 97 49.7 69 98 50.3 69
Resected 108 50 46.3 70 58 53.7 68
Not resected 87 47 54.0 70 40 46.0 67
Other adenocarcinomas1 42 22 52.4 67 20 47.6 68
Controls
DNA- typed blood donors 379 189 49.9 39 190 50.1 44
Serotyped hospital patients 6149 2805 45.6 66 3344 54.4 64
1See Materials and Methods for description.
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42 other adenocarcinomas located within the pancreas. 
The latter group consisted of intraductal papillary muci-
nous neoplasm (5 cases) or mucinous cystic neoplasm 
with malignant component (1 case), intrapancreatic adeno-
carcinoma of the ampulla/papilla of Vateri (19 cases) or 
of ductus choledochus (9 cases), and unspecified adeno-
carcinoma of the pancreas (8 cases).
For the statistical comparison, two different control 
groups were employed (Table 1). One consisted of 379 
healthy blood donors from Haukeland University Hospital 
(49.9% females) that were genotyped in the same way as 
the cases. The other control group contained 6149 patients 
(45.6% females) born before 1.1.1970 and admitted to 
the same hospital during a randomly chosen period of 
six consecutive months in 2007. All patients had been 
blood- typed by serological means as part of their health 
care. No selection with regard to diagnosis was done.
DNA extraction and genotyping
EDTA- blood, frozen tissue and formalin- fixed paraffin- 
embedded (FFPE) tissue blocks were used for DNA extrac-
tion from the 237 pancreatic adenocarcinoma cases. DNA 
from frozen buffy coats from EDTA- blood (195 cases) 
were purified using MagAttract DNA Blood Midi M48 
kit on the BioRobot M48 workstation (both from Qiagen, 
Hilden, Germany) or manually processed with the E.Z.N.A 
DNA extraction kit (Omega Bio- Tek, Norcross, GA, USA), 
according to the manufacturers’ protocol. For 38 cases, 
only FFPE tissue samples were available; 10- micron sec-
tions were then sliced and subjected to manual depar-
affinization with xylene, followed by ethanol washes before 
overnight incubation at 56°C with Proteinase K (Qiagen) 
and processing with the E.Z.N.A. DNA extraction kit. For 
the final four cases, only fresh- frozen tissue samples were 
available. These were incubated directly with Proteinase 
K and then processed as the FFPE samples. DNA from 
the blood donor controls was isolated from EDTA- blood 
buffy coats using the same purification system as for the 
patient blood samples.
Genotyping was performed using TaqMan predesigned 
genotyping assays (Cat. No. 4351379; Applied Biosystems, 
Foster City, CA). Each sample was tested for three com-
mon SNPs at the ABO locus (Table S1): rs8176704 (intron 
3) for the A2 allele (Assay ID: C_30336657_10), rs8176746 
(exon 7) for the B allele (Assay ID: C_25610772_20), and 
rs505922 (intron 1) for the O allele (Assay ID: 
C_2253769_10). The samples were also screened for the 
FUT2 variant rs601338 (Assay ID: C_2405292_10), which 
determines secretor status of ABH antigens.
The genotyping assays were performed on the 7900 
Fast Real- time PCR System with the corresponding 
7900 Fast System SDS 2.4 Software (Applied Biosystems). 
Positive and negative controls were included to ensure 
appropriate clustering. Each assay was performed using 
10 ng template DNA, TaqMan Universal Master Mix buffer 
(Applied Biosystems), and 20x primer and probe mix as 
recommended by the manufacturer. Thermal cycling was 
performed by first activating the DNA polymerase at 95°C 
for 10 min and then running 40 amplification cycles, 
each consisting of denaturation at 92°C for 15 sec and 
combined annealing/extension at 60°C for 1 min.
Quality control
Misclassification of ABO genotypes was expected to be 
minimal, as genotyping results from the three different 
ABO SNPs matched the haplotype phasing of the ABO 
gene (Table 1 in [13]) for all analyzed samples. In addi-
tion, we compared our genotyping results for 40 cases 
(20 extracted from blood and 20 from FFPE tissues) with 
serologically determined ABO status as stated in the 
patients’ medical records. The concordance rate was 100%. 
Genotyping quality for the blood donor control group 
was assessed by testing for Hardy–Weinberg equilibrium 
using the Haploview Software [21]. The distribution of 
genotypes was as expected from the SNP frequencies.
Statistical analysis
Each SNP was tested under various genetic models 
 (dominant, codominant, recessive, additive) using the 
software PLINK (http://pngu.mgh.harvard.edu/~purcell/plink). 
Assess ment of differences in genotype or phenotype dis-
tributions between cases and controls was carried out by 
the two- tailed Fisher`s exact test or Pearson`s chi- square 
test. Odds ratios (OR) and 95% confidence intervals (CI) 
were calculated using two- by- two contingency table analysis 
on the SISA webpage (http://www.quantitativeskills.com/
sisa). Survival analysis was performed using the software 
package STATISTICA version 12 (StatSoft, Tulsa, OK). 
The Product–Limit (Kaplan–Meier) Analysis Module was 
employed for comparing survival between groups by log- 
rank test of significance. Survival times versus cumulative 
proportion surviving, according to breakdown by blood 




From our biobank of patients with pancreatic tumors, 
we initially selected the patients diagnosed with adeno-
carcinoma of the exocrine gland. This cohort consisted 
of 237 cases (50.2% females), with a median age at 
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diagnosis of 69 years in both sexes (Table 1). We reviewed 
all cases to identify those that were consistent with a 
diagnosis of PDAC (n = 195, 82.3%). The cases were 
also classified according to whether or not the tumor had 
been judged resectable at the time of diagnosis (Table 1).
Association between ABO blood group and 
pancreatic cancer risk
The genotype frequencies for all adenocarcinoma cases 
and blood donor controls are given in Table S2. In both 
groups, the most common ABO genotypes were A1O and 
OO, and the least frequent were BB and A2A2. We first 
compared allele frequencies of A1, A2, B, and O in the 
whole adenocarcinoma cohort with frequencies observed 
in the blood donors (Table 2, ‘All cases’). The A1 allele 
frequency was higher among the patients (22.4% vs. 17.9%) 
but the difference did not quite reach statistical significance 
(P = 0.057). When the analysis was limited to PDAC 
cases only, there was a significant difference in A1 fre-
quency (23.8% vs. 17.9%; OR = 1.43, CI = 1.06–1.93; 
P = 0.018). Interestingly, the A2 frequency appeared almost 
identical between the groups compared (7.6–7.8%). The 
B and O allele frequencies varied, but were not statisti-
cally different.
For the further analyses, we restricted our analysis to 
the PDAC cases only. We deduced ABO phenotypes from 
the genotype data of the cases and the blood donors. 
The blood group distributions are shown in Table 3. The 
blood group A prevalence was clearly different (50.8% 
vs. 40.6%; OR = 1.51, CI = 1.06–2.13; P = 0.021,) and, 
in keeping with the data of Table 2, the subgroup A1 
frequencies fully explained the observed difference (42.6% 
vs. 29.3%; OR = 1.79, CI = 1.25–2.56; P = 0.001). Moreover, 
the prevalence of blood group O was lower in cases than 
in controls (33.8% vs. 42.7%; OR = 0.69, CI = 0.48–0.98; 
P = 0.039). Blood group B did not show a statistically 
significant difference in distribution. Neither did blood 
group AB, although in this case, the number of subjects 
was too small for meaningful comparisons to be made.
Healthy blood donors may not always serve as an opti-
mal control group in case–control studies [22]. We therefore 
collected information on ABO blood group distribution 
from a large control cohort of unselected hospitalized 
patients (see Materials) from the same geographical region 
as our pancreatic cancer patients. The subgroup A1/A2 
distribution was not known for the hospitalized patient 
cohort. Notably, the hospitalized patients had a significantly 
higher blood group A prevalence than the blood donors 
(45.8% vs. 40.6%; OR = 1.24, CI = 1.00–1.53; P = 0.049). 
Similarly, blood group B was significantly less frequent 
(7.7% vs. 12.1%; OR = 0.60, CI = 0.44–0.83; P = 0.002). 
Blood group O had very similar prevalence in the two 
control groups (42.7% and 42.9%).
When the PDAC blood group distribution was compared 
with that of the hospitalized patients, the enrichment of 
blood group A among the PDAC cases no longer reached 
statistical significance (50.8% vs. 45.8%; OR = 1.22, 
CI = 0.92–1.62; P = 0.173) (Table 4). On the other hand, 
the blood group B difference was now significant (12.8% 
vs. 7.7%; OR = 1.76, CI = 1.15–2.71; P = 0.009). The 
lower frequency of blood group O in the PDAC cohort 
remained significant with almost identical odds ratio (33.8% 
vs. 42.9%; OR = 0.68, CI = 0.50–0.92; P = 0.012).
Tumor resectability
To further explore the association between blood group 
frequencies and PDAC, the patients were stratified into 
two subgroups: those who had their pancreatic tumor 
resected and those who were considered surgically unre-
sectable at the time of cancer diagnosis (Table 1). The 
latter group consisted of patients with locally advanced 
tumors with encasement of adjacent large blood vessels 
(Clinical stage III) or with metastatic disease at the time 
of diagnosis (Clinical stage IV) [23]. We observed that 
Table 2. ABO and FUT2 allele frequencies of blood donor controls compared with pancreatic cancer cases.
Allele
Controls 
(n = 758) All cases (n = 474) PDAC cases only (n = 390)
% % P OR (95% CI) % P OR (95% CI)
ABO
A1 17.9 22.4 0.057 1.32 (0.99–1.75) 23.8 0.018 1.43 (1.06–1.93)
A2 7.8 7.6 1.000 0.97 (0.63–1.50) 7.7 1.000 0.99 (0.63–1.56)
B 8.7 7.6 0.491 0.86 (0.56–1.32) 7.7 0.556 0.87 (0.56–1.37)
O 65.6 62.4 0.266 0.87 (0.69–1.11) 60.8 0.109 0.81 (0.63–1.05)
FUT2
Se 51.5 51.5 1.000 1.00 (0.79–1.26) 52.1 0.847 1.02 (0.80–1.31)
Se0 48.5 48.5 1.000 1.00 (0.79–1.26) 47.9 0.847 0.98 (0.77–1.25)
n, number of genotyped alleles; PDAC, pancreatic ductal adenocarcinoma; P, P - value from chi- square test (df = 1); OR (95% CI), odds ratio (95% 
confidence interval). Significant P- value is shown in bold face.
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the blood group A and subgroup A1 prevalences were 
highest among the unresected cases (54.0% and 44.8%, 
respectively) and both were significantly different from 
the frequencies found in blood donors (A: OR = 1.72, 
CI = 1.07–2.74, P = 0.023; A1: OR = 1.96, CI = 1.22–3.16, 
P = 0.005) (Table 3). Moreover, the unresected cases had 
the lowest frequency of blood group O (28.7% vs. 42.7%; 
OR = 0.54, CI = 0.33–0.90; P = 0.016). A comparison 
with the cohort of hospitalized patients (Table 4) revealed 
significant differences for the unresected patients, both 
with regard to blood group B (14.9% vs. 7.7%; OR = 2.11, 
CI = 1.16–3.83; P = 0.012) and blood group O (28.7% 
vs. 42.9%; OR = 0.54, CI = 0.34–0.86; P = 0.008).
Survival
Data on survival after time of diagnosis was available for 
all PDAC cases. As expected, survival was significantly 
better among resected than among unresected cases 
(median survival 18.1 months vs. 5.6 months, respectively; 
P < 0.001) (Fig. 1A). Given that blood group is a risk 
factor for PDAC and that it also may influence resection 
status, we also analyzed survival according to ABO phe-
notype. When all 195 patients were classified as O or 
non- O cases, survival of the two groups was not signifi-
cantly different (median 10.4 vs. 9.3 months, respectively; 
P = 0.23) (Fig. 1B). We then looked at resected and 
unresected cases separately. Among the resected cases, 
survival did not differ between patients with O and non- O 
blood group (P = 0.93) (Fig. 1C). However, in the group 
of unresected cases, patients with blood group O survived 
longer than non- O patients (median 6.7 vs. 5.5 months, 
respectively; P = 0.04) (Fig. 1D). When the non- O cases 
were split into blood group A or B and compared to 
the O cases, the difference in survival reached significance 
for blood group B (median 2.7 months; P = 0.03), but 
not for A (median 5.6 months; P = 0.14) (Fig. 1E–F). 
Although it should be noted that the number of A2 cases 
Table 3. ABO blood group and secretor phenotype frequencies of blood donor controls compared with PDAC cases.
Phenotype Controls 
(n = 379) 
%
PDAC cases (n = 195) PDAC cases according to resection status
Resected (n = 108) Unresected (n = 87)
% P OR (95% CI) % P OR (95% CI) % P OR (95% CI)
ABO
A 40.6 50.8 0.021 1.51 (1.06–2.13) 48.1 0.163 1.36 (0.88–2.09) 54.0 0.023 1.72 (1.07–2.74)
A1 29.3 42.6 0.001 1.79 (1.25–2.56) 40.7 0.024 1.66 (1.07–2.59) 44.8 0.005 1.96 (1.22–3.16)
A2 11.3 8.2 0.241 0.70 (0.38–1.27) 7.4 0.238 0.63 (0.29–1.37) 9.2 0.562 0.79 (0.36–1.75)
B 12.1 12.8 0.814 1.06 (0.63–1.79) 11.1 0.771 0.91 (0.46–1.78) 14.9 0.478 1.27 (0.65–2.47)
AB1 4.5 2.6 0.359 0.56 (0.20–1.54) 2.8 0.586 0.61 (0.18–2.12) 2.3 0.548 0.50 (0.11–2.21)
O 42.7 33.8 0.039 0.69 (0.48–0.98) 38.0 0.374 0.82 (0.53–1.27) 28.7 0.016 0.54 (0.33–0.90)
FUT2
Secretor 77.6 76.4 0.753 0.94 (0.62–1.41) 72.2 0.248 0.74 (0.46–1.22) 81.6 0.410 1.28 (0.71–2.32)
Non- secretor 22.4 23.6 0.753 1.07 (0.71–1.61) 27.8 0.248 1.33 (0.82–2.16) 18.4 0.410 0.78 (0.43–1.41)
PDAC, pancreatic ductal adenocarcinoma; P, P - value from chi- square test (df=1); OR (95% CI), odds ratio (95% confidence interval). Significant 
P - values are shown in bold face.
1P - values from two- tailed Fisher`s exact test.
Table 4. ABO phenotypic frequencies of hospital patient controls compared with PDAC cases.
Blood types Controls 
(n = 6149) 
%
PDAC cases (n = 195) PDAC cases according to resection status
Resected (n = 108) Unresected (n = 87)
% P OR (95% CI) % P OR (95% CI) % P OR (95% CI)
A 45.8 50.8 0.173 1.22 (0.92–1.62) 48.1 0.632 1.10 (0.75–1.61) 54.0 0.128 1.39 (0.91–2.12)
B 7.7 12.8 0.009 1.76 (1.15–2.71) 11.1 0.188 1.50 (0.82–2.75) 14.9 0.012 2.11 (1.16–3.83)
AB1 3.5 2.6 0.690 0.72 (0.29–1.76) 2.8 1.000 0.78 (0.25–2.47) 2.3 0.771 0.64 (0.16–2.62)
O 42.9 33.8 0.012 0.68 (0.50–0.92) 38.0 0.301 0.81 (0.55–1.20) 28.7 0.008 0.54 (0.34–0.86)
PDAC, pancreatic ductal adenocarcinoma; P, P- value from chi- square test (df=1); OR (95% CI), odds ratio (95% confidence interval). Significant 
P - values are shown in bold face.
1P- values from two- tailed Fisher`s exact test
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Figure 1. Cumulative proportion survival (Kaplan–Meier) plot for the 195 pancreatic ductal adenocarcinomas according to breakdown by resection 
status and blood group phenotype. (A)-(F) Pairwise comparison of subgroups as specified in the heading of each panel. The observed survival times 
(months along the X- axis) are indicated by circles (complete) or crosses (censored observations). In panel A, survival curves for resected and unresected 
cases are shown by a blue and a red line, respectively. In all other panels, survival curves for blood group O and the comparison group are shown by 
a red and blue line, respectively.
A All cases - unresected versus resected  B All cases – group O versus non-O 
C Resected cases – group O versus non-O D Unresected cases – group O versus non-O 
E Unresected cases – group O versus A F Unresected cases – group O versus B 
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is relatively small (16/195 cases), we also examined whether 
there was a survival difference between patients of blood 
group A1 and A2. Neither among all cases nor when cases 
were classified according to resection status was any sta-
tistically significant difference observed (data not shown).
Secretor status
Because the secretion of soluble H antigen is associated 
with susceptibility to multiple pathogens through adherence 
to the gastrointestinal mucosa we looked at the secretor 
phenotype determined by the rs601338 FUT2 polymorphism 
(Tables S1, S2). Consistent with another study [13], there 
were no significant differences in prevalence of alleles or 
phenotypes when compared with the blood donor controls 
(Tables 2, 3). We further checked whether FUT2 could 
have an effect on resection status by comparing the groups 
of resected and unresected PDAC cases in Table 3 directly 
against each other. The difference in secretor status was 
not significant (72.2% vs. 81.6%; OR=0.59, CI=0.30–1.16; 
P = 0.124). Finally, we examined if secretor status might 
associate with survival in our patient cohort. No such 
association was seen (Fig. S1).
Discussion
A variety of biological traits have been linked to ABO 
histo- blood group phenotypes. Reported associations 
include, among others, plasma lipid levels [24], suscep-
tibility to H. pylori–associated disorders [25], cardiovascular 
disease [26], and cancer [27]. Here, we have investigated 
ABO genetic variants and phenotypes in the context of 
pancreatic cancer. A strength of our study is that a re- 
evaluation of the recorded pancreatic adenocarcinomas 
was performed to select only those cases consistent with 
a diagnosis of PDAC. Thus, from our initial cohort of 
adenocarcinomas with an anatomical location in the pan-
creas, 42 (17.7%) cases were excluded. Materials of pan-
creatic head cancers may contain a significant number of 
adenocarcinomas originating from the distal bile duct, 
ampulla, or duodenum [28], and proper classification of 
cases collectively regarded as pancreatic cancer should 
always be attempted.
One limitation of our study is the relatively low number 
of cases and blood donor controls. Another relates to the 
selection of control groups, which may pose a challenge 
for ABO phenotype and other traits with a distribution 
that varies by geography and ethnicity. The optimal control 
group for our study would have been randomly drawn 
individuals from the population of Western Norway, 
matched to cases by age, sex and county of residence. 
However, such a cohort could not be obtained within 
the restrictions of the present study.
We confirmed the association between the blood group 
O phenotype and reduced susceptibility to pancreatic 
exocrine cancer (frequency of 33.8% in cases versus 42.7% 
and 42.9% in the two control groups). When comparing 
with blood donors, blood group A was significantly over-
represented among cases. We made the interesting obser-
vation that the association with blood group A was 
explained by the A1 allele/blood group only, a finding 
previously reported by a few papers [13, 29]. Serology- 
based analyses and many genetic studies of ABO blood 
groups in pancreatic cancer do not distinguish between 
A1 and A2 subgroups. However, this distinction might be 
of biological importance as A1 and A2 glycosyltransferases 
display different catalytic activities, the A2 isoform having 
a higher Km and an estimated enzyme activity 30–50 times 
lower than A1 [14]. The finding that A1, but not A2, 
associates with pancreatic cancer could therefore suggest 
a role of blood group A glycosyltransferase activity in 
carcinogenesis.
Studies of associations between ABO blood groups and 
human disease are challenging for at least two reasons. 
Firstly, across the globe there are important variations in 
ABO frequencies, reflecting human migration movements 
and possibly also selection pressures from the environment 
[30, 31]. Within Norway, the ABO distribution differs 
according to geographical localization with the highest 
blood group O frequency observed in the Western part 
of the country and the highest B frequency in the north-
ernmost region [32]. Secondly, healthy blood donors might 
not always serve as appropriate controls for epidemiological 
studies in general and, studies of ABO in particular. There 
could, for example, be a bias in ABO distribution among 
donors because of the association of blood groups with 
a variety of diseases. Another potential selective effect 
could arise in that certain blood groups might be preferred 
as donors.
In the literature, it is well established that blood group 
O individuals have a lower risk of pancreatic cancer [33]. 
For the other blood types, the data are not always con-
sistent. Some authors report an association with blood 
group A, but not with B [29, 34] whereas others describe 
an association with B, but not with A [20] or even find 
AB to be protective [35]. One reason for this discrepancy 
might therefore be the way that control groups have 
been selected. We employed two different sets of controls: 
a limited number of blood donors and a large number 
of random patients from the same geographical area as 
our patients. The control groups exhibited very similar 
blood group O frequencies (close to 43%). Thus, we 
found a very consistent protective effect of blood group 
O on PDAC risk. On the other hand, the frequencies 
of blood groups A and B varied considerably among the 
two control groups, resulting in a significant association 
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of PDAC risk with blood group A when blood donors 
were used and with blood group B when employing 
hospital patients. Interestingly, in a recent large study 
where 1.6 million blood donors from Denmark and Sweden 
were followed over an average of 17 years, there was 
increased risk for pancreatic cancer in subjects with blood 
group A when compared with O subjects [36]. Blood 
group B did not associate with increased risk, that is, a 
result similar to what we observed when using blood 
donors as controls.
We also analyzed ABO blood group distribution in the 
context of resectability at the time of diagnosis (Tables 3 
and 4). In this respect, it should be noted that our cases 
were recruited at a surgical department to which patients 
usually are referred when they are to be evaluated for 
operation. Thus, those PDAC patients that at the time 
of diagnosis obviously are unresectable will be clearly 
underrepresented. This explains the relatively high fraction 
of operated patients in our material (55.4%) compared 
with the general low resection rate for pancreatic adeno-
carcinomas, which is around 20%.
We divided our PDAC patients into those who under-
went surgery to remove the primary tumor (Clinical stages 
I and II) and those who presented with an unresectable 
tumor (Stages III and IV). In the latter group, the O 
phenotype frequency dropped to 28.7% and the A1 and 
B frequencies increased to 44.8% and 14.9%, respectively 
(Table 3). Thus, the ABO frequency differences that we 
observed for the whole PDAC group versus the control 
groups appeared more prominent when analyzing unre-
sected cases only. This suggests an association between 
ABO phenotype and clinical stage which again could 
indicate that blood group O subjects diagnosed with pan-
creatic cancer have the best prognosis. Previous analyses 
in this regard are discrepant. In a study involving Han 
Chinese patients, blood group O subjects had better out-
come that those with non- O blood group [37]. However, 
in a German material, although the incidence of blood 
group O was significantly lower among the investigated 
cohort of pancreatic cancer patients, no association was 
seen between ABO status and survival [38]. Intriguingly, 
when we analyzed unresected cases only, there was a sig-
nificant association between having blood group O and 
better survival (Fig. 1D–F). This effect was not seen when 
the group of resected cases were analyzed according to 
blood group O status (Fig. 1C). Overall, the data from 
our material indicate that individuals with blood group 
O may have somewhat less aggressive PDACs than patients 
having other blood groups.
The implication of ABO glycosyltransferases in pancreatic 
cancer is still enigmatic. There is, however, strong evidence 
that the expression of ABH antigens in the gastrointestinal 
tract affects the anchoring efficiency of certain pathogenic 
strains to the mucosa and influences bacterial and/or viral 
colonization and infectivity [39]. In this context, H. pylori 
infection as risk factor in pancreatic pathologies has been 
extendedly researched [40], and it was shown that the 
increased risk of non- O individuals for PDAC became 
even greater if these subjects were positive for the CagA- 
negative H. pylori strain [41]. FUT2 secretor status seems 
to affect the composition of the intestinal microbiota [42] 
and the susceptibility to certain gastrointestinal infections 
[43]. Nevertheless, we did not observe a difference in 
FUT2 allele distribution or phenotype among pancreatic 
cancer cases and controls, similar to what a previous 
report showed [13]. Similarly, there was no association 
between secretor phenotype and survival (Fig. S1).
Naturally occurring alloantibodies (i.e., isoagglutinins) 
could also play a role in the association between ABO 
blood groups and pancreatic cancer. These antibodies 
provide immunity against pathogens expressing blood 
group- like antigens on their surface. Anti- A and anti- B 
isoagglutinins, present in the plasma of blood group O 
individuals, have been shown to react toward the Tn and 
T pancarcinoma antigens [44]. Tn and T may be struc-
turally related to A and B blood group antigens, respec-
tively [45] and could possibly render cancer cells 
immunologically less recognized in blood group A and 
B individuals.
In conclusion, although the choice of control material 
involves some particular challenges when studying ABO 
blood groups as a disease risk factor, our results confirm 
both a genetic and phenotypic association with pancreatic 
ductal adenocarcinoma. We found that the increased sus-
ceptibility connected with blood group A is likely to be 
caused by the subtype A1 only, and we suggest that also 
clinical stage at the time of diagnosis and survival could 
be influenced by blood group status. However, the biol-
ogy behind the fascinating ABO- pancreatic cancer link is 
poorly understood, and studies are warranted on how 
ABO glycosyltransferase activity may influence biological 
aggressiveness of pancreatic neoplastic cells.
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